Last reviewed · How we verify
Ropivacaine 1%
At a glance
| Generic name | Ropivacaine 1% |
|---|---|
| Sponsor | Sunnybrook Health Sciences Centre |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- OMT for Adhesive Capsulitis (PHASE4)
- Suprainguinal Fascia Iliaca Block With vs Without Dexmedetomidine (PHASE4)
- Does the Common Practice of Adding Diluted Epinephrine in Tranverse Abdominal Plan Block to Ropivacaine Significantly Decrease the Peak Systemic Resorption of Ropivacaine? (NA)
- The Effects of Various Concentrations of Ropivacaine on the Onset and Duration of Ankle Blocks (NA)
- Patient-Titrated Automated Intermittent Boluses of Local Anesthetic vs. a Continuous Infusion Via a Perineural Catheter for Postoperative Analgesia (PHASE4)
- Integrative Bilateral Cervical Sympathetic Blocks for Trauma-Related Symptoms in Special Operations Veterans: A Prospective Case Series
- Mid-transverse Process Combined With Erector Spinae Block Versus Paravertebral Plane Block (NA)
- External Oblique Intercostal Block Versus Erector Spinae Plane Block on Postoperative Pain in Laparoscopic Radical Gastrectomy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ropivacaine 1% CI brief — competitive landscape report
- Ropivacaine 1% updates RSS · CI watch RSS
- Sunnybrook Health Sciences Centre portfolio CI